<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

NCI-H460

Description

NCI-H460 (Lung Cancer CDX Model)

The NCI-H460 line was derived from a patient with large cell lung carcinoma, a subtype of non-small cell lung cancer (NSCLC). It carries KRAS and STK11 mutations, reflecting clinically relevant drivers of lung cancer. NCI-H460 has been widely used in biomarker and therapeutic research. Its stability supports translational oncology studies.

Key Features:

  • Derived from large cell lung carcinoma (NSCLC).
  • KRAS and STK11 mutations.
  • Represents aggressive lung cancer biology.
  • Tumorigenic in xenograft models.

Applications:
NCI-H460 is applied in NSCLC drug discovery and biomarker validation. Researchers use it to evaluate KRAS-targeted and combination therapies. It is frequently employed in studies of drug resistance and lung cancer progression. Its reproducibility ensures reliable preclinical outcomes.

Details
Tumor Type
Lung
Tumor Subtype
NA
Organism
Human
Mouse Sex
Female
Mouse Strain
Athymic Nude
Mutated Genes
ARID1A
Mutation: p.I2135_L2136del
Effect: Inframe Deletion
*Data provided by DepMap
KRAS
Mutation: p.Q61H
Effect: Missense Variant
Impact: Pathogenic & Likely Pathogenic
*Data provided by DepMap
PIK3CA
Mutation: p.E545K
Effect: Missense Variant
Impact: Not Provided & Likely Pathogenic & Pathogenic & Pathogenic / Likely Pathogenic
*Data provided by DepMap
STK11
Mutation: p.Q37Ter
Effect: Stop-Gain
Impact: Likely Pathogenic & Pathogenic
*Data provided by DepMap
Expression Data (provided by DepMap)
Growth Curve
View on Lumin